Oruka Therapeutics reported second quarter 2026 financial results and provided a corporate update. The company announced that its EVERLAST-B Phase 2b trial for ORKA-001 is fully enrolled, with Week 16 data expected in the fourth quarter of 2026 to support a Phase 3 program starting in early 2027. Additionally, the ORCA-SURGE trial for ORKA-002 has accelerated, with Week 16 data now expected in the first quarter of 2027. The company initiated the ORCA-SPLASH Phase 2 trial for ORKA-002 in hidradenitis suppurativa and announced that its novel antibody ORKA-004 will enter clinical trials in the fourth quarter of 2026. Financially, Oruka reported a net loss of $41.2 million and held $1.1 billion in cash, which is expected to fund operations through an anticipated BLA filing for ORKA-001. The company operates as a clinical-stage biotechnology firm developing biologics for chronic skin diseases.